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Abstract
Background: Recently, there has been renewed interest in the link between cholesterol and prostate cancer. It has been
previously reported that in vitro, prostate cancer cells lack sterol-mediated feedback regulation of the major transcription
factor in cholesterol homeostasis, sterol-regulatory element binding protein 2 (SREBP-2). This could explain the
accumulation of cholesterol observed in clinical prostate cancers. Consequently, perturbed feedback regulation to
increased sterol levels has become a pervasive concept in the prostate cancer setting. Here, we aimed to explore this in
greater depth.
Methodology/Principal Findings: After altering the cellular cholesterol status in LNCaP and PC-3 prostate cancer cells, we
examined SREBP-2 processing, downstream effects on promoter activity and expression of SREBP-2 target genes, and
functional activity (low-density lipoprotein uptake, cholesterol synthesis). In doing so, we observed that LNCaP and PC-3
cells were sensitive to increased sterol levels. In contrast, lowering cholesterol levels via statin treatment generated a greater
response in LNCaP cells than PC-3 cells. This highlighted an important difference between these cell-lines: basal SREBP-2
activity appeared to be higher in PC-3 cells, reducing sensitivity to decreased cholesterol levels.
Conclusion/Significance: Thus, prostate cancer cells are sensitive to changing sterol levels in vitro, but the extent of this
regulation differs between prostate cancer cell-lines. These results shed new light on the regulation of cholesterol
metabolism in two commonly used prostate cancer cell-lines, and emphasize the importance of establishing whether or not
cholesterol homeostasis is perturbed in prostate cancer in vivo.
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Introduction
The study of cholesterol homeostasis in a prostate cancer (PCa)
setting began in 1942, when Swyer published in situ findings of
elevated cholesterol levels in benign prostatic hyperplasia com-
pared to normal tissue [1]. More recently, there has been renewed
interest in the links between cholesterol and PCa [2–4]. For
instance, it has been proposed that an in-depth understanding of
cholesterol regulation in PCa progression may lead to the
development of novel drug targets [5]. In line with this, several
epidemiological studies have reported an association between the
use of statins (cholesterol-lowering drugs) and reduced risk of
advanced PCa (reviewed in [2–4]).
Cholesterol has an important influence on membrane integrity,
signaling, and metabolism, and thus there is a need to regulate its
levels within the cell [2]. One major homeostatic mechanism
occurs at the transcriptional level, via the master transcription
factor: sterol-regulatory element binding protein 2 (SREBP-2).
The regulation of this transcription factor has been reviewed by
Brown and Goldstein [6]. Briefly, SREBP-2 is synthesized as a
precursor, bound to the endoplasmic reticulum (ER). When
cholesterol levels are low, SREBP-2 is transported from the ER to
the Golgi apparatus, where it is processed to release the N-
terminal domain. This mature form of SREBP-2 migrates into the
nucleus, where it upregulates cholesterogenic genes, such as those
encoding the low-density lipoprotein receptor (LDLR) and 3-
hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). This
promotes the uptake and synthesis of cholesterol until cholesterol
levels are sufficient, after which SREBP-2 is retained in the ER,
preventing its activation and thus downregulating target gene
expression. This sterol-dependent feedback mechanism also
regulates the SREBP-1a/c isoforms. In general, SREBP-1c
preferentially upregulates fatty-acid-related genes, SREBP-2
targets cholesterol-related genes, and SREBP-1a can activate both
[7,8].
It has been suggested that that this feedback regulation of
SREBP-2 is lacking in PCa, through the observation that
treatment with sterols reduced SREBP-2 target gene expression,
as well as low-density lipoprotein (LDL) uptake, in normal cells but
not in PC-3 and DU145 PCa cells in vitro [9]. Perturbations in
sterol-mediated feedback would explain the accumulation of
cholesterol in PCa specimens [10,11], and has become a widely-
accepted concept in the PCa setting (reviewed in [3,4]). This
dysregulation implies that PCa cells, and perhaps cancer cells in
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not conform to the currently-held paradigm of cellular cholesterol
homeostasis [16]. An accumulation of cholesterol within the cell
would, for instance, stiffen the mitochondrial membrane, reducing
oxidative phosphorylation – this promotes glycolysis even in
the presence of oxygen (the Warburg effect [17]), a metabolic
phenotype commonly observed in cancer cells and of great interest
in cancer research [18].
The aim of our investigation was to explore cholesterol
regulation in greater depth in two commonly used PCa cell-lines,
PC-3 and LNCaP, using a variety of conditions and approaches.
We sought to confirm previous findings of SREBP-2 activity being
unaffected by sterols [9], and determine if this dysregulation affects
the response of PCa cells to lowered sterol levels. From our results,
we provide a new perspective on cholesterol homeostasis in these
PCa cell-lines, having implications for both laboratory experi-
ments and PCa therapy.
Results
Sterol-mediated regulation of SREBP-2 target genes
exists in prostate cancer cells
To examine sterol regulation of SREBP-2 in the first instance,
we analyzed the mRNA expression of two SREBP-2 target genes
(LDLR, HMGCR) upon manipulating the cholesterol status of PC-3
and LNCaP cells. Experiments were conducted under lipoprotein-
deficient conditions (with lipoprotein-deficient fetal calf serum
[FCLPDS]) to enhance the effects of treating cells with 25-
hydroxycholesterol (25-HC), an oxygenated cholesterol derivative
(oxysterol), and LDL. LDL delivers cholesterol via the LDLR,
presenting a physiological alternative for increasing intracellular
sterol levels.
If regulation of SREBP-2 is present, the addition of sterols,
through either 25-HC or LDL treatment, would reduce SREBP-2
processing and SREBP-2 target gene expression. On the other
hand, the statin compactin (also known as mevastatin) inhibits
HMGCR, which catalyses a rate-limiting step in cholesterol
synthesis, and thus should increase SREBP-2 activity. The non-
cancerous cell-lines, prostate epithelial cells (PrEC) and fibroblasts
(FB), served as a control, demonstrating both forms of feedback
regulation (Fig. 1A). Similar sterol-mediated regulation was also
observed in the PCa cell-lines (Fig. 1A), contrary to previous
findings [9].
In PC-3 cells, increasing cellular sterol status with 25-HC or
LDL significantly reduced lipogenic gene expression, in compar-
ison to the vehicle condition (Fig. 1A). The similarity between
vehicle- and compactin-treated PC-3 cells is unlikely due to
resistance to compactin, since we found that compactin inhibits
cholesterol synthesis in PC-3 cells by metabolic labeling (data not
shown). In contrast, compactin significantly increased lipogenic
gene expression in LNCaP cells and sterol-treated LNCaP cells
had similar expression patterns to the vehicle-treated cells (Fig. 1A).
Overlaying the relative mRNA expression data from each cell-line
(Fig. 1B) showed that the PCa cells (solid lines) had a reduced
Figure 1. Sterol-mediated regulation of SREBP-2 target genes exists in PCa cells. Cells were treated with the statin compactin (CPN, 5 mM),
oxysterol 25-HC (1 mg/ml), or LDL (50 mg/ml) for 24 h. Cellular RNA was harvested and mRNA expression of the LDLR and HMGCR genes was analyzed
by qRT-PCR. The mRNA levels were made relative to the vehicle condition as described in Materials and Methods. Data are mean + SEM, from 3
separate experiments for each cell-line. Each experiment was performed with triplicate wells per condition. (A) Data presented separately for each
cell-line. * p,0.05, ** p,0.01, two-sample t-test versus vehicle condition. (B) Data from (A) has been overlaid for each gene, represented as
mean6SEM for each datapoint. The PCa cell-lines are represented by solid lines, whilst the non-PCa cell-lines are represented by broken lines.
doi:10.1371/journal.pone.0008496.g001
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affected by LDL than both non-PCa cell-lines. Nevertheless, these
PCa cell-lines were both sensitive to changes in cholesterol status.
Sterol-mediated regulation is specific to SREBP-2
Given that the expression of two SREBP-2 target genes (LDLR,
HMGCR) responded similarly to changing cholesterol status
(Fig. 1), we sought more direct evidence that this effect was
mediated by the SREBP-2 transcription factor.
Since mature SREBP-2 binds to the sterol-regulatory element
(SRE) within a target gene’s promoter region, we developed an
SRE-specific luciferase assay, utilizing the LDLp-588luc plasmid
[19], which encodes firefly luciferase under the transcriptional
regulation of the LDLR promoter. Using site-directed mutagenesis,
we disrupted the SRE within the promoter region to generate a
negative control plasmid, LDLp-mutSRE. We found that the wild-
type promoter (LDLp-588luc) exhibited the predicted changes in
luciferase activity (increasing with compactin treatment, decreas-
ing with 25-HC or LDL treatment), whilst the mutant promoter
(LDLp-mutSRE) produced negligible changes (Fig. S1). The
mutant promoter luciferase activity was subtracted from that of
the wild-type promoter for each treatment condition to obtain
SRE-specific activity. This luciferase assay revealed that feedback
regulation occurred in PCa cells in response to altered cholesterol
levels (Fig. 2A).
In LNCaP cells, SRE-specific activity (Fig. 2A) appeared more
sensitive than SREBP-2 target gene expression (Fig. 1) to sterol
treatment. Consequently, overlaying the data for each cell-line
(Fig. 2B) revealed that each cell-line was affected similarly by sterol
treatment. In contrast, compactin treatment again demonstrated
that PC-3 and LNCaP cells differ in the extent of their homeostatic
responses: SRE-specific activity was greatly increased in LNCaP
cells compared to the non-PCa cell-lines (dotted lines), in contrast
to PC-3 cells (Fig. 2B). Interestingly, in PrEC cells, the response to
compactin (Fig. 2A) was blunted in comparison to SREBP-2 target
gene expression (Fig. 1A). This suggests that other transcription
factors may alter the effects of SREBP-2 on target gene expression,
justifying the use of the SRE-specific luciferase assay.
However, the SREBP-1a isoform also binds to the same SREs
as SREBP-2 with strong affinity [7], potentially confounding these
results. Hence, we tested whether this effect was SREBP-2-specific
by Western blotting. Since the IgG-1C6 anti-SREBP-2 antibody
binds to the C-terminus [20], it detects the C-terminal cleavage
product, giving an indication of SREBP-2 processing. For
instance, sterols would promote the retention of SREBP-2
precursor in the ER [21], reducing cleaved SREBP-2. We found
that 25-HC reduced SREBP-2 cleavage in all three prostate cell-
lines, whilst compactin increased SREBP-2 cleavage in PrEC and
LNCaP cells, but not in PC-3 cells (Fig. 2C). Thus, the degree of
SREBP-2 processing correlated with the regulation of promoter
Figure 2. Responses to changing sterol status involve SREBP-2 activation in prostate cancer cells. (A) Cells were transfected as described
in Materials and Methods. Treatment included the statin compactin (CPN, 5 mM), oxysterol 25-HC (1 mg/ml), or LDL (50 mg/ml) for 24 h. SRE-specific
luciferase activity was determined as described in Materials and Methods, and normalized to the vehicle condition. The wildtype and mutant
promoter values are shown in Fig. S1. Data are mean + SEM, from 3 separate experiments for each cell-line. Each experiment was performed with
triplicate wells per condition. * p,0.05, ** p,0.01, two-sample t-test versus vehicle condition. (B) Data from (A) has been overlaid, represented as
mean6SEM for each datapoint. The PCa cell-lines are represented by solid lines, whilst the non-PCa cell-lines are represented by broken lines. (C) Cells
were treated with CPN (5 mM) or 25-HC (1 mg/ml) for 24 h. Cell lysates were subjected to SDS-PAGE and Western blotted with the IgG-1C6 anti-SREBP-
2 antibody. The C-terminal cleavage product of SREBP-2, SREBP-2(C), is labeled with an arrow – we assume that the band below is a non-specific
band. Probing for a-tubulin served as an internal loading control. The blot shown is representative of at least 2 separate experiments for each
cell-line.
doi:10.1371/journal.pone.0008496.g002
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observed in these PCa cell-lines. Overall, this data shows that PC-3
and LNCaP cells are both sensitive to sterols, but differ in their
responses to compactin treatment.
Changes in SREBP-2 activity translate to the functional
level in PCa cells
To see if transcriptional regulation exerts homeostatic effects on
cholesterol metabolism in PCa cells, we examined the effects of
altering sterol status on LDLR activity and cholesterol synthesis.
The activity of LDLR was determined using an LDL uptake
assay. Following incubation with DiI-LDL (LDL labeled with the
fluorescent dye DiI), the subsequent fluorescence of the cells
provided an indication of LDL uptake. Since LDL is internalized
at 37uC, but not 4uC [22], each experiment was performed twice
simultaneously, with one set of cells incubated with DiI-LDL at
37uC and the other at 4uC – the difference in fluorescence
between the two sets provided a measure of internalized DiI-LDL.
This also controlled for non-specific binding of DiI-LDL. This
assay revealed that, relative to the vehicle condition, 25-HC
caused a significant decrease in DiI-LDL internalization in all cell-
types (Fig. 3A). In contrast, compactin increased LDLR activity in
LNCaP cells only, having no significant effect in PrEC cells and
causing a decrease (albeit not significant, p=0.08) in PC-3 cells
(Fig. 3A).
To determine cholesterol synthesis, cells were radiolabeled after
treatment. The 25-HC treatment was maintained during radio-
labeling, whilst the compactin treatment was removed – since
compactin would reduce cholesterol synthesis, we instead
attempted to simulate the ‘statin rebound effect’ [23]. This
phenomenon is a homeostatic response to compactin: normally,
compactin increases SREBP-2 processing (Fig. 2B), upregulating
the expression of cholesterol synthetic enzymes. Consequently,
when compactin is removed, due to the high levels of enzymes
present, there will be a large flux through the pathway. This
ironically causes an acute increase in cholesterol levels. This can be
observed in PrEC and LNCaP cells (Fig. 3B). However, compactin
pre-treatment surprisingly reduced cholesterol synthesis during
radiolabeling in PC-3 cells (Fig. 3B). Despite this, 25-HC abolished
cholesterol synthesis in all three cell-lines (Fig. 3B).
Taken together, these data demonstrate that regulation of both
cholesterol uptake (via LDL) and synthesis are sensitive to sterol
levels in PCa cells.
Basal SREBP-2 activity is higher in PC-3 cells than in
LNCaP cells
Whilst both PC-3 and LNCaP cell-lines are sterol-responsive,
SREBP-2 activity in PC-3 cells appeared less sensitive to lowered
cholesterol levels (compactin treatment, Figs. 1, 2). These
experiments were conducted under lipoprotein-deficient condi-
tions (Medium C), whilst a two-fold increase in SRE-specific
activity was observed with compactin treatment (relative to the
vehicle treatment) under full-serum conditions (Fig. 4). This
suggests that in PC-3 cells, the compactin effect is masked by
‘saturation’ of SREBP-2 processing in lipoprotein-deficient media,
such that further cholesterol deprivation via compactin treatment
would have little effect. This further implies that PC-3 cells are not
insensitive to compactin per se, but require less sterol deprivation
to maximize SREBP-2 activity compared to other cell-lines,
including the LNCaP cells.
This important difference between LNCaP and PC-3 cells was
explored further. As a case-study, the baseline regulation and
activity of LDLR were considered under lipoprotein-deficient
conditions, from experiments described in Figs 1–3. Firstly,
Figure 3. Sterol feedback regulation has functional effects in
PCa cells. Cells were treated with the statin compactin (CPN, 5 mM) or
the oxysterol 25-HC (1 mg/ml) for 24 h in Medium C. (A) Cells were
prepared, treated, and assayed for DiI-LDL internalization as described
in Materials and Methods. The amount of DiI-LDL internalized provides
an indication of LDLR activity. Data are presented as mean + SEM, from
at least 3 separate experiments for each cell-line. Each experiment was
performed with triplicate wells per condition. (B) After treatment, cells
were washed with PBS and radiolabeled with [1-
14C]-acetic acid for 2 h.
Radiolabeling was performed in the presence of treatment, with the
exception of the CPN treatment (in which case the CPN was absent).
Cells were then harvested and lipid extracts were subjected to thin layer
chromatography and phosphorimaging as described in Materials and
Methods. The phosphorimages shown are representative of at least 3
separate experiments for each cell-line. Densitometry was performed
and data presented as mean+SEM for each cell-line. * p,0.05,
** p,0.01, two-sample t-test versus vehicle condition.
doi:10.1371/journal.pone.0008496.g003
Figure 4. SRE-specific activity is saturated under lipoprotein-
deficient conditions in PC-3 cells. PC-3 cells were transfected as
described in Materials and Methods. Treatment included the statin
compactin (CPN, 5 mM) or oxysterol 25-HC (1 mg/ml) for 24 h, in either
full-serum (Medium A) or lipoprotein-deficient serum (Medium C). SRE-
specific luciferase activity was determined as described in Materials and
Methods, and normalized to the vehicle condition. Data are mean + SD,
representative of 2 separate experiments. Each experiment was
performed with triplicate wells per condition.
doi:10.1371/journal.pone.0008496.g004
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threshold of 10
21.5 normalized fluorescence units were compared
between PC-3 and LNCaP cells. The Ct values for the
housekeeping gene, porphobilinogen deaminase (PBGD), were
similar between the two cell-lines (p<0.73), justifying this
comparison. The average LDLR DCt value was ,2 units lower
in PC-3 cells, indicating a 4-fold higher basal LDLR mRNA
expression than LNCaP cells (Fig. 5A). Subsequently, basal LDLR
activity was also significantly higher in PC-3 cells (Fig. 5B).
Together with Fig. 2C, this implies that basal SREBP-2 activity
is higher in PC-3 cells. However, other transcription factors may
also contribute to the expression of SREBP-2 target genes. Hence,
previous SRE-specific luciferase experiments were re-analysed.
For the vehicle condition, the relative luciferase activity generated
by the LDLp-mutSRE (mutated SRE in LDLR promoter) was
considered as a proportion of that of LDLp-588luc (wildtype
LDLR promoter). The mutSRE-fluc luciferase activity was
assumed to represent non-SRE activity since compactin and
25-HC treatment had little effect on LDLp-mutSRE activity in all
cell-lines (Fig. S1). The mutSRE-fluc/LDLR-fluc proportion was
higher in PC-3 cells than LNCaP cells (Fig. 5C), implying other
transcription factors may also contribute to the differences in
LDLR mRNA expression observed between these cell-lines
(Fig. 5A). Taken together, these data suggest that basal activity
downstream of SREBP-2 is upregulated in PC-3 cells, resulting in
a maximal response under basal conditions.
Discussion
In this investigation, we sought to gain insight into cellular
cholesterol homeostasis in the PCa setting. An aberrant feedback-
response to sterols appears to be a common phenomenon in
cancer cells [9,12–15] and would explain the accumulation of
cholesterol in clinical PCa [10,11]. Our findings suggest that
sterol-regulated processing of SREBP-2 exists in PCa cells
(Fig. 2C). Consequently, sterol feedback regulation had down-
stream effects at the SRE (Fig. 2B), on the expression of SREBP-2
target genes (Fig. 1B), and at the functional level (Fig. 3). We also
considered the response of these cells to reduced sterol levels,
finding that PC-3 and LNCaP cells differed in their degrees of
regulation (Fig. 5).
In PC-3 cells, sterols caused a significant decrease in SREBP-2
activity, conflicting with previous findings [9]. Besides methodo-
logical considerations, such as quantitative versus semi-quantita-
tive methods of mRNA determination, other factors may account
for the discrepancy with their findings. For instance, it has been
shown that colonic adenocarcinoma cells were unaffected by
sterols at higher densities, but demonstrated feedback regulation
when plated at lower densities [14]. Cells at lower densities are
exponentially growing, with higher cholesterol uptake and
synthesis rates found in both cancerous and normal cells [14,24].
This could allow for the reconciliation of the findings here with
those of the previous study [9], particularly since their experiments
were run for a longer duration (30 and 45 h, versus 24 h here). We
plated PC-3 cells at low density, to prevent overconfluence at 48 h,
and found sensitivity to sterols up to 48 h (Fig. S2).
Similarly, sterols were found to reduce SREBP-2 activity in
LNCaP cells (Fig. 2). Here, there was a slight decrease in SREBP-2
target gene expression (Fig. 1), whilst cholesterol uptake and
synthesis was abolished (Fig. 3). This is supported by a previous
finding that sterols downregulated the expression of HMG-CoA
synthase, another SREBP-2 target, in LNCaP cells [25]. Hence,
PCa cells are indeed sensitive to increased sterol levels. This does
not negate the idea of disrupted sterol-feedback in PCa cells, but
rather raises more questions: do laboratory PCa cell-lines
accumulate cholesterol as is seen in clinical PCa [10,11]? Would
PCa cells be less sensitive to sterols in an in vivo context, such as in
xenografts? Clearly, this warrants further investigation.
We also examined the reverse situation, reducing cholesterol
levels using the statin compactin. Similarly to PrEC cells, this
increased SREBP-2 activity (Fig. 2), enhanced SREBP-2 target
gene expression (Fig. 1), and induced a statin-rebound effect in
cholesterol synthesis (Fig. 3B) in LNCaP cells. Interestingly,
compactin did not affect LDLR activity in PrEC cells (Fig. 3A),
whilst it has been proposed that statins reduce blood-cholesterol
levels by increasing LDLR expression (seen here in Fig. 1A) and
thus LDL uptake [26]. This apparent paradox may be explained
since PCSK9 (proprotein convertase subtilisin/kexin type 9),
another SREBP-2 target, has been found to promote LDLR
degradation, limiting the effectiveness of statins [27,28]. LNCaP
cells appear to bypass this regulatory mechanism (Fig. 3A),
demonstrating increased LDLR activity upon compactin treat-
ment. Overall, this shows that LNCaP cells respond to low sterol
levels.
In contrast, compactin did not cause a significant increase in
SREBP-2 target gene expression (Fig. 1) in PC-3 cells, relative
to the vehicle condition. Compactin was confirmed to inhibit
Figure 5. Basal LDLR gene expression and activity is higher in
PC-3 than LNCaP cells. Data was pooled from experiments where
LNCaP and PC-3 cells received vehicle treatment in Medium C for 24 h.
(A) For each qRT-PCR experiment, the DCt values (for threshold=10
21.5
normalized fluorescence units) for the LDLR gene, relative to the PBGD
housekeeping gene, were considered. Expression is represented as a
fold change (relative to PC-3 cells), whereby a one-unit increase in DCt
results in a two-fold decrease in mRNA expression. Data are presented
as mean + SEM, from at least 4 separate experiments for each cell-line.
(B) Raw LDL uptake, measured as fluorescence normalised by protein
content in the LDL uptake assay, was averaged between experiments
and made relative to the PC-3 cells. Data are presented as mean + SEM,
from at least 3 separate experiments for each cell-line. (C) For each SRE-
specific luciferase assay, the firefly/Renilla luciferase ratios generated
from the LDLp-mutSRE plasmid were normalised to that of the LDLp-
588luc plasmid. Data presented as mean+SEM, from at least 5 separate
experiments for each cell-line. Each experiment in (A)–(C) was
performed with triplicate wells per condition. * p,0.05, ** p,0.01,
two-sample t-test versus PC-3 cells. (D) A model depicting the
differences in cholesterol homeostasis between PC-3 and LNCaP cells.
The threshold level of cellular cholesterol, at which SREBP-2 activity
becomes dramatically reduced, may be higher in PC-3 cells. This would
reduce the effect of statins, relative to the basal condition.
doi:10.1371/journal.pone.0008496.g005
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compactin effect is likely due to near-maximal SREBP-2
processing from incubation in the lipoprotein-deficient media
(Fig. 4). Supporting this, the basal levels of processed SREBP-2
appear to be highest in PC-3 cells (Fig. 2C), and basal LDLR
expression and activity were higher in PC-3 than LNCaP cells
(Fig. 5A,B). Thus, PC-3 cells require less sterol deprivation in
order to invoke a maximum response from the SREBP-2 pathway.
Furthermore, compactin treatment tended to reduce LDLR
activity (Fig. 3A) and pretreatment lowered cholesterol synthesis
(Fig. 3B), for reasons that are currently unclear.
Therefore, PC-3 and LNCaP cells vary in their cholesterol
homeostasis. Radhakrishnan et al. [29] propose a ‘switch-like
control’ of SREBP-2 activity, whereby a sharp drop in SREBP-2
processing occurs when intracellular (ER-)cholesterol levels reach
a precise threshold. We propose that this ‘regulatory gauge’ is
higher in PC-3 cells (Fig. 4D), accounting for 1) PC-3 cells having
higher basal SREBP-2 than LNCaP cells, 2) statins appearing to
have little effect in PC-3 cells (relative to the basal condition), and
3) sterols reducing SREBP-2 activity in both PCa cell-lines.
This difference in cholesterol regulation may be attributed to
other phenotypic differences between these cell-lines, such as
androgen responsiveness. LNCaP cells are androgen-sensitive
[30], whilst PC-3 cells are relatively androgen-independent [31].
Androgens have been shown to upregulate SCAP expression,
subsequently increasing SREBP-2 activation [32]. Since a lack of
feedback regulation was previously observed in the androgen-
independent PCa cell-lines (PC-3, DU145) [9], it has been argued
that disrupted sterol feedback may be associated with androgen
deprivation because SREBP-2 was upregulated in LNCaP
xenografts in vivo upon host castration [33]. However, this cannot
be reconciled with our results since PC-3 cells were found to be
sterol-sensitive here. Nevertheless, a factor involved in androgen-
independence may favor PC-3 cells, potentially raising baseline
SREBP-2 activity. Alternatively, other transcription factors may
contribute to SREBP-2 target gene expression (Fig. 5C), such as
oncostatin M binding to the SIRE (sterol-independent response
element) within the LDLR promoter [34], augmenting basal
cholesterol metabolism in PC-3 cells. Further investigations are
needed to delineate the precise mechanisms by which cholesterol
homeostasis differs in these PCa cell-lines – in light of this, a recent
paper has reported differences in the transcriptional profile
between LNCaP and PC-3 cells [35], albeit not directly related
to cholesterol homeostasis.
Consequently, our findings support the assertion that these two
cell-lines cannot be treated as synonymous examples of PCa cell-
lines for in vitro studies [35,36]. However, it is difficult to relate
these findings to a clinical setting because, to the best of our
knowledge, no studies have examined the sterol-mediated
regulation of SREBP-2 and cholesterol metabolism in cells isolated
from prostate specimens. In addition, there have been conflicting
reports on the expression profile of PCa in a sterol-related context.
For instance, in recent studies examining the changing profile with
progression to the metastatic, hormone-refractory state: some
studies found an increase in the expression of SREBP-2 [37] and
sterol biosynthetic [38] genes, whilst another found a decrease
[39]. Such conflicts may result from differences in patient
populations, sample preparations, or microarray platforms
(reviewed in [40]).
Nevertheless, it has been argued that LNCaP cells are more
characteristic of clinical PCa than PC-3 cells [41,42]. Hence, the
findings here may have clinical ramifications: in particular,
LNCaP cells have higher LDLR activity in response to compactin
treatment. This suggests that treatment with a cholesterol-lowering
drug (such as a statin) may induce LDL uptake specifically in PCa
cells. This implies that concurrent administration of such tumor-
specific chemotherapeutic agents, incorporated into LDL or other
LDLR-binding vesicles [43,44], may provide a potential treatment
option for PCa.
Materials and Methods
Materials
Non-cancerous human PrEC cells were obtained from Lonza
(Mt Waverley, Vic, AU), human foreskin FB cells were a gift from
Dr Ingrid Gelissen (University of New South Wales, AU), PC-3
cells were a gift from Dr Qihan Dong (University of Sydney, AU),
and LNCaP cells were a gift from Dr Pamela Russell (Prince of
Wales Hospital, AU).
The LDLp-588luc plasmid is a luciferase reporter plasmid
containing the LDLR promoter region [19], and was a gift from Dr
Thierry Grand-Perret (GlaxoSmithKline, FR). The LDLp-
mutSRE plasmid was derived from the LDLp-588luc plasmid
using site-directed mutagenesis, as described below. The phRL-
TK plasmid expresses Renilla luciferase constitutively, serving as a
transfection control, and was obtained from Promega (Annandale,
NSW, AU).
The IgG-1C6 mouse anti-SREBP-2 primary antibody [20] was
obtained from BD Biosciences (North Ryde, NSW, AU). The B-5-
1-2 mouse anti-a-tubulin primary antibody [45] was obtained
from Sigma-Aldrich (Castle Hill, NSW, AU). Peroxidase-conju-
gated AffiniPure donkey anti-mouse secondary antibody was
obtained from Jackson ImmunoResearch Laboratories (Sydney
Markets, NSW, AU).
DMSO, NaCl, and all solvents (analytical grade) used for thin
layer chromatography were obtained from Ajax FineChem (Taren
Point, NSW, AU). Glycerol was obtained from B.D.H. Chemicals
(Port Fairy, Vic, AU). 40% Acrylamide/bis-acrylamide solution,
and Precision Plus Protein Kaleidoscope standard biomarkers
were obtained from Bio-Rad Laboratories (Regents Park, NSW,
AU). Isopropanol, methanol, HCl, and NaOH were obtained
from Crown Scientific (Moorebank, NSW, AU). RPMI medium
1640, fetal calf serum (FCS), and penicillin-streptomycin were
obtained from Invitrogen (Mt Waverley, Vic, AU). 1-bromo-3-
chloropropane, bromophenol blue, bovine serum albumin,
compactin (mevastatin), b-mercaptoethanol, l,l9-dioctadecyl-
3,3,39,39-tetramethylindocarbocyanine perchlorate (DiI), Dulbec-
co’s PBS, primers, SDS, Tween20, and Tris-base were obtained
from Sigma-Aldrich (Castle Hill, NSW, AU). 25-HC was obtained
from Steraloids (RI, USA). [1-
14C]-acetic acid (specific activity:
56.0 mCi/mmol) was obtained from GE Healthcare (Rydalmere,
NSW, AU).
FCLPDS was prepared from FCS as described previously [22]
and diluted to 30 mg/ml with 0.15 M NaCl. LDL was prepared by
standard ultracentrifugation techniques (d=1.01921.063 g/ml)
from the plasma of healthy male volunteers [46]. PBST was 0.1%
(v/v) Tween20 in PBS. DiI-labeled LDL (DiI-LDL) was prepared
by incubating DiI with undesalted LDL (3:10 w/w ratio) for 18 h at
37uC, and purifying the resulting DiI-LDL using the PD-10
chromatography column (GE Healthcare, Rydalmere, NSW, AU),
according to the manufacturer’s instructions.
Cell culture
PC-3, LNCaP, and FB cells were maintained in Medium A
(RPMI 1640, supplemented with 10% [v/v] FCS, 100 U/mL
penicillin and 100 mg/mL streptomycin [PS]). Transfections were
performed in Medium B (Medium A without antibiotics) and
treatment was in Medium C (RPMI 1640, supplemented with
Cholesterol Regulation in PCa
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cells, plates and dishes were treated with 0.1 mg/ml poly-L-lysine
(R&D Systems, Gymea, NSW, AU) for 1 h to enhance cellular
adhesion. PrEC cells were maintained and treated in PrEGM
(Lonza, Mt Waverley, Vic, AU), and transfected in PrEGM
without antibiotics. Similar results were obtained when LNCaP
cells were treated in PrEGM or Medium C (data not shown). Cells
were plated to obtain 70–90% confluence at the end of the
treatment.
Quantitative real-time reverse-transcription polymerase
chain reaction (qRT-PCR)
Following treatment in experiments examining the expression of
SREBP-2 target genes, total RNA was harvested, reverse
transcribed to cDNA, and mRNA levels determined (from cDNA)
by qRT-PCR, as previously described [47]. Primers used to
amplify human LDLR, HMGCR, and PBGD cDNA have been
previously described [46,48]. Amplification data was analyzed
using Rotor-Gene Version 6.0 (Build 27) (Corbett Research,
Mortlake, NSW, AU). Melting curve analysis was performed to
confirm the production of a single product in each reaction. The
mRNA expression levels of HMGCR and LDLR genes were
normalized to PBGD and made relative to the vehicle condition
using the DDCt method.
Site-directed mutagenesis
In order to examine activity more specific to SREBP-2, the SRE
within the LDLR promoter region of the LDLp-588luc reporter
plasmid [19] was mutated using site-directed mutagenesis. The
SRE sequence was mutated from 59-ATCACCCCAC-39 to 59-
ATCACGGCTC-39 (mutations underlined), previously shown to
prevent SREBP-2 binding [49]. This was performed using 50 ng
template DNA and the iProof High-Fidelity DNA polymerase
(Bio-Rad, Regents Park, NSW, AU), according to the manufac-
turer’s instructions, with the addition of 6% (v/v) DMSO to
enhance reaction efficiency. The forward primer was 59-
AAGACATTTGAAAATCACGGCTCTGCAAACTCCTCCC-
CCTG-39 (mutations underlined), and the reverse primer was
the forward primer’s reverse-complement. The reaction product
was then treated using the QuikChange II XL Site-Directed
Mutagenesis Kit (Stratagene, CA, US), according to the
manufacturer’s instructions. The mutation was confirmed by
sequencing. The mutant plasmid was labeled ‘LDLp-mutSRE’.
Luciferase assay
For each experiment, cells were plated in two 100 mm dishes
and transfected with either LDLp-588luc or LDLp-mutSRE
(10 mg), and both cotransfected with phRL-TK (1 mg) as a
transfection control. These transfections were performed using
Lipofectamine LTX transfection reagent, Plus reagent, and
OptiMEM I (all obtained from Invitrogen, Mt Waverley, Vic,
AU), according to the manufacturer’s instructions. After 4 h, cells
were then split into 24-well plates in Medium C (LNCaP, PC-3,
FB) or PrEGM (PrEC), and allowed to adhere overnight. Since
LNCaP cells adhere poorly to culture dishes [30], the washing and
media-refreshment were avoided for all cell-lines. Rather, the
treatment was delivered in a small quantity of plating medium,
added to the existing media in the wells.
After treatment, the luciferase assays were conducted using the
Dual-Luciferase Reporter Assay System (Promega, Annandale,
NSW, AU), according to the manufacturer’s instructions.
Luciferase activity was measured using a Veritas luminometer
(Turner Designs, CA, US), and expressed as change in firefly
luciferase activity relative to Renilla luciferase activity. The mutant
promoter (LDLp-mutSRE) luciferase activity was subtracted from
the wild-type promoter (LDLp-588luc) luciferase activity to obtain
SRE-specific activity for each experimental condition.
Western blotting
For experiments where SREBP-2 processing was examined,
cells were harvested for protein and protein aliquots (30 mg) were
subjected to 10% (w/v) SDS-PAGE, and transferred to Trans-Blot
transfer medium (Bio-Rad, Regents Park, NSW, AU), as
previously described [47]. Membranes were blocked in 5% (w/v)
skim milk, 5% (v/v) FCS PBST, for 1 h at room temperature. This
was followed by incubation in primary antibody for 2 h (for anti-
SREBP-2) or 1 h (for anti-a-tubulin) at room temperature,
washing with PBST 3 times for 10 min, incubation in secondary
antibody for 1 h at room temperature, and washing with PBST 3
times for 10 min. Antibodies were visualized on Hyperfilm (GE
Healthcare, Rydalmere, NSW, AU) using the ECL detection
system (Millipore, North Ryde, NSW, AU). The anti-SREBP-2
antibody (IgG-1C6) detects the C-terminal product of mature
SREBP-2 at ,68 kDa [20], confirmed by inputting the amino
acid sequence of the human SREBP-2 C-terminal fragment
(SREBP-2 sequence obtained from UniProt Accession Number
Q12772) into Compute pI/Mw Tool (ExPASy, Geneva, CH).
Between antibodies, membranes were treated with a stripping
buffer (25 mM glycine [pH 2], 1.5% [w/v] SDS). Films were
scanned using HP Scanjet G3010 and accompanying software
(Hewlett-Packard, CA, USA).
LDL uptake assay
To quantify LDLR activity, the LDL uptake assay was
performed as previously described [50,51], with modifications.
Briefly, cells were seeded in duplicate plates in Medium C (FB,
PC-3, LNCaP) or PrEGM (PrEC) and allowed to adhere
overnight. Treatment was delivered in a small quantity of plating
medium, added to the existing media in the wells – there were
triplicate wells for each treatment condition, performed in
duplicate. After treatment, DiI-LDL was added to each well
(obtaining a final DiI concentration of 10 mg/ml protein), and for
2 h, one set of cells was incubated at 37uC and the other at 4uC.
Cells were then washed once with PBS and lysed with lysis buffer
(0.1 M NaOH, 0.1% [w/v] SDS). Cell lysate was assayed for
fluorescence using an Fmax microplate spectrofluorometer
(Molecular Devices, CA, US) at excitation l=544 nm and
emission l=612 nm, and for protein content using the BCA
assay kit (Pierce, Paddington, Qld, AU). Fluorescence was
normalized to protein content for each sample. For each treatment
condition, the difference between the normalized DiI-LDL
fluorescence of cells incubated at 37uC and 4uC determined
internalized DiI-LDL.
Cholesterol synthesis assay
Following treatment, cells were labeled with 1 mCi/well
[1-
14C]-acetic acid for 2 h in the presence of treatment, after
which lipids were extracted and separated by thin layer
chromatography, as previously described [46], with the exception
that the mobile phase used in the chromatography was
hexane:diethyl ether:glacial acetic acid (60:40:1, v/v/v). After
development, the band corresponding to cholesterol was visualized
using the FLA-5100 phosphorimager (Fujifilm, Tokyo, JP). The
relative intensities of bands were quantified using Sciencelab
ImageGauge 4.0 software (Fujifilm, Tokyo, JP).
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Data are presented as means, with errors bars as SEMs. Two-
sample t-tests were used to assess statistical differences between
treatments: p,0.05 (two-tailed) was considered significant. Statis-
tical tests were performed using Microsoft Excel 2003 (Microsoft,
USA).
Supporting Information
Figure S1 The wild-type luciferase construct (LDLp-588luc)
responds to changing sterol levels, whilst the mutant luciferase
construct (LDLp-mutSRE) does not. Cells were transfected as
described in Materials and Methods. Treatment included the
statin compactin (CPN, 5 mM), oxysterol 25-HC (1 mg/ml),
or LDL (50 mg/ml) for 24 h. The luciferase assay was performed
as described in Materials and Methods. The firefly:Renilla
ratio of each treatment was normalized to vehicle condition
to obtain relative luciferase activity. Data are mean +SEM,
from 3 separate experiments for each cell-line. Each experiment
was performed with triplicate wells per condition.
Found at: doi:10.1371/journal.pone.0008496.s001 (0.94 MB TIF)
Figure S2 Sterol-mediated regulation of SREBP-2 target genes
exists in PC-3 cells over varying time periods. PC-3 cells were
treated with the statin compactin (CPN, 5 mM) or oxysterol 25-HC
(1 mg/ml) for the times indicated. The mRNA expression of the
LDLR and HMGCR genes were analyzed as described in Fig. 1,
and made relative to the 0 h vehicle condition. Data are mean +
SEM, from 3 separate experiments. Each experiment was
performed with triplicate wells per condition. * p,0.05, **
p,0.01, two-sample t-test versus vehicle condition at that
respective time-point.
Found at: doi:10.1371/journal.pone.0008496.s002 (0.38 MB TIF)
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